Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein for the treatment of PD and other neurodegenerative diseases; and recombinant human CDNF protein. The company was incorporated in 2008 and is based in Espoo, Finland.